1
Return

Ivacaftor affects the susceptibility of standard-of-care drugs used to treat Mycobacterium abscessus lung disease

delete2025-06-04
delete0
delete
OA
AI
S
Shrivastava, Avneesh
S
Sanjay Singh
G
Gunavanthi D. Boorgula
G
Galvez, Rodolfo-Amaro
S
Shashikant Srivastava *
DOI：10.1128/aac.00030-25delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Patients with cystic fibrosis have dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR), and this predisposes them to nontuberculous mycobacteria (NTM), including Mycobacterium abscessus (MAB), infection. We found that one of the CFTR modulators, ivacaftor, kills MAB in a concentration-dependent manner, with killing efficacy comparable to amikacin and imipenem, drugs in guideline-based regimens. Using clinical isolates of MAB, amikacin 1/4x MIC concentration combined with ivacaftor killed 2.67 log10 CFU/mL MAB.
Keywords:
nontuberculous mycobacteria
cystic fibrosis
CFTR modulator
susceptibility

Journal

Antimicrobial Agents and Chemotherapy cover
Antimicrobial Agents and Chemotherapy
IF:
4.5
Papers:
2.3W
Citations:
6.2W

Organization

U
Univ Texas Tyler
Scholars:
50
Papers: 30
Citations: 10
Cited Papers

Cited Papers

Citing Papers

Citing Papers